Patent Rebuff For Roche’s Valcyte In India, Again
Roche’s powder formulation for Valcyte (valganciclovir) has failed to secure a patent in India, at least for now, with the patent office seeing no ‘technical advancement’ in the invention.
You may also be interested in...
Roche and the Medicines Patent Pool have signed a five-year deal that will allow developing countries to achieve faster access to the Swiss company’s CMV drug, Valcyte for 90% less.
India has set aside a patent on Roche's Valcyte (valganciclovir) used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.